Omalizumab effective for chronic spontaneous urticaria

February 13, 2018

(HealthDay)—Omalizumab, alone or in combination with a short-term course of corticosteroids, is highly effective for the treatment of refractory chronic spontaneous urticaria (CSU), according to a study published online Feb. 5 in the International Journal of Dermatology.

Nikolaos Syrigos, M.D., from Sotiria General Hospital in Athens, Greece, and colleagues retrospectively evaluated from 20 (mean age 54.5 years; 75 percent women) with refractory CSU in order to assess correlations between demographic, clinical, and laboratory characteristics and omalizumab treatment outcomes.

The researchers found that mean disease duration before omalizumab administration was 21.8 months. All patients responded favorably to omalizumab after one to five doses, with 85 percent of patients having a complete response. The remaining three patients had well-controlled disease after omalizumab treatment. In 30 percent of patients, the best response to omalizumab was achieved after interval administration of a nine-day course of methylprednisolone (total dose of 188 mg). A shorter disease duration before initiation of omalizumab was significantly correlated with late response to omalizumab (after three-month treatment).

"In the present series, , either alone or in combination with a short-term course of corticosteroids, was highly effective in resolution of refractory CSU," the authors write.

Explore further: Intranasal omalizumab does not increase serum IgE levels

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Intranasal omalizumab does not increase serum IgE levels

November 22, 2017
(HealthDay)—In patients with birch pollen allergy, intranasal administration of omalizumab does not result in relevant change of allergen-specific and total immunoglobulin E (IgE) levels, according to a pilot study published ...

Omalizumab effective for chronic spontaneous urticaria

March 31, 2016
(HealthDay)—Omalizumab is effective in patients with moderate-to-severe chronic spontaneous urticaria (CSU) symptoms and angioedema unresponsive to high doses of antihistamine treatment, according to a study published online ...

Omalizumab protects against early, late allergic responses

June 9, 2017
(HealthDay)—For patients with a significant response to allergen challenge, omalizumab induces protective effects against early (EAR) and late allergic reactions (LAR), according to a study published online June 5 in Allergy.

Markers that predict omalizumab response identified

May 2, 2016
(HealthDay)—Baseline serum periostin levels and levels of serum free immunoglobulin E (IgE) during treatment follow-up may be useful in assessing response to omalizumab treatment for asthma, according to a study published ...

Asthma drug helps patients with skin disorder

April 7, 2017
Patients who develop itchy wheals in response to cold or friction benefit from treatment with omalizumab, a drug normally used to treat asthma. Two separate clinical studies, conducted by researchers from Charité - Universitätsmedizin ...

Omalizumab decreases colds in inner-city children with asthma, study reports

March 6, 2016
Treatment with omalizumab significantly decreases the number of colds in inner-city children with allergic asthma, researchers reported at a press conference today at the American Academy of Allergy, Asthma and Immunology ...

Recommended for you

Breakthrough in designing a better Salmonella vaccine

September 24, 2018
UC Davis researchers announce in the Proceedings of the National Academy of Sciences this week a breakthrough in understanding which cells afford optimal protection against Salmonella infection—a critical step in developing ...

Antifungal agent found to be possible treatment for porphyria

September 24, 2018
A large team of researchers from Spain, France and the U.S. has found that a common antifungal agent might be useful as a treatment for a rare type of porphyria. In their paper published in the journal Science Translational ...

New findings on the muscle disease Laing early-onset distal myopathy

September 24, 2018
New avenues are now being opened toward treatment of Laing distal myopathy, a rare disorder that causes atrophy of the muscles in the feet, hands and elsewhere. In a study published in the journal PNAS, researchers have identified ...

Insulin shows great potential against chronic colitis

September 24, 2018
Diabetes is not the only disease on which insulin has an effect, it appears. In a new study using tests on mice, researchers from the University of Copenhagen, among others, have discovered a new method for treating chronic ...

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.